Histomorphometric and immunohistochemical assessment of treated dentin matrix delivered by platelet-rich fibrin for socket preservation in rabbit model
BMC Oral Health,
Journal Year:
2025,
Volume and Issue:
25(1)
Published: Feb. 12, 2025
This
study
aimed
to
test
treated
dentine
matrix
(TDM)
with
platelet-rich
fibrin
(PRF)
for
socket
preservation,
following
tooth
extraction
compared
synthetic
grafting
material
Nanobone
(NB)
PRF.
Study
was
conducted
on
New
Zealand
rabbits
(n
=
40).
Bilateral
first
lower
premolar
performed,
one
side
left
empty
and
the
other
filled
in
group
20).
In
20),
TDM/PRF
while
NB/
After
three
months,
were
euthanized,
area
examined
using
haematoxylin
eosin
(H&E)
Goldner
Masson
trichrome
stains.
One-way
ANOVA
post-hoc
tests
used
histomorphometric
analysis.
Immunohistochemical
analysis
of
osteopontin
carried
out.
Histological
NB/PRF
groups
showed
a
higher
level
new
bone
formation
comparison
control
PRF
groups.
Histomorphometric
revealed
significant
increase
after
months
(p
0.042
p
<
0.001),
respectively.
There
no
differences
percentages
unmineralized
between
at
both
intervals
0.375
0.352,
respectively).
Regarding
immunohistochemistry,
highest
immune
expression
followed
by
TDM/PRF.
No
detected
0.234
&
0.607
ability
form
sockets
rabbits.
can
be
as
an
alveolar
preservation.
Language: Английский
Evaluation of the usefulness of platelet-rich fibrin (PRF) in mandibular third molar surgery with 3D facial swelling analysis: a split-mouth randomized clinical trial
Head & Face Medicine,
Journal Year:
2025,
Volume and Issue:
21(1)
Published: Feb. 22, 2025
Third
molar
surgery
is
associated
with
various
postoperative
complications
(PC).
Different
strategies,
including
the
application
of
platelet-rich
fibrin
(PRF),
have
been
implemented
to
reduce
PC.
Digital
technologies
proven
useful
in
objectively
assessing
facial
swelling.
This
study
aimed
evaluate
effect
PRF
on
reducing
swelling
after
lower
third
using
a
3D
face
scanner.
A
randomized
split-mouth
clinical
trial
was
set
up
and
32
patients
(18
years),
requiring
extraction
both
mandibular
molars,
were
recruited
at
Oral
Surgery
Clinic
Magna
Graecia
University
Catanzaro.
The
primary
predictive
variable
or
not
plugs
membranes
post-extraction
socket.
Primary
outcome
recorded
scanner
preoperatively
(T0),
three
(T1)
seven
(T2)
days.
Qualitative
quantitative
data
analysis
conducted
following
an
automated
standardized
imaging
workflow
Slicer
software.
Secondary
variables
trismus,
by
measuring
maximum
buccal
opening
caliper,
pain,
visual
analogue
scale
(VAS),
duration
surgery.
Descriptive
bivariate
performed
setting
significance
level
$$\:\alpha\:$$
=
0.05.
All
exhibited
significant
increase
T1,
followed
subsequent
reduction
from
day
3
7,
slight
persistence
edema
observed
seventh
day.
No
emerged
statistical
conducted.
Linear
differences
group
reported
improved
values
only
T1-T2
T0-T2
phases
analysis.
Volumetric
favored
compared
control
all
phases.
VAS
T2,
group.
Application
sockets
showed
effectiveness
Its
advantages,
accessibility,
cost-effectiveness,
absence
adverse
reactions,
make
it
optimal
treatment
choice
post-surgical
sequelae.
Language: Английский
Applications of Platelet-Rich Fibrin (PRF) Membranes Alone or in Combination with Biomimetic Materials in Oral Regeneration: A Narrative Review
Biomimetics,
Journal Year:
2025,
Volume and Issue:
10(3), P. 172 - 172
Published: March 11, 2025
Platelet-rich
fibrin
(PRF)
membranes
are
a
biomaterial
derived
from
the
patient’s
own
blood,
used
in
different
medical
and
dental
areas
for
their
ability
to
promote
healing,
tissue
regeneration,
reduce
inflammation.
They
obtained
by
centrifuging
which
separates
components
concentrates
platelets
growth
factors
matrix.
This
material
is
then
moulded
into
membrane
that
can
be
applied
directly
tissues.
The
use
of
these
PRF
often
associated
with
biomimetic
materials
such
as
deproteinized
bovine
bone
mineral
(DBBM),
β-tricalcium
phosphate
(β-TCP),
enamel
matrix
derivative
(EMD),
hydroxyapatite
(HA).
Different
indications
have
been
proposed,
like
alveolar
ridge
preservation,
augmentation,
guided
regeneration
(GTR),
sinus
floor
augmentation.
aim
this
narrative
review
check
state-of-the-art
analyze
existing
gaps
combination
Language: Английский
EFFECT OF CLINDAMYCIN ON HUMAN OSTEOBLASTS TREATED WITH ZOLEDRONATE: AN IN VITRO STUDY
Archives of Oral Biology,
Journal Year:
2025,
Volume and Issue:
unknown, P. 106247 - 106247
Published: April 1, 2025
Language: Английский
Efficacy of concentrated growth factor combined with coronally advanced flap in the treatment of gingival recession: a systematic review and meta-analysis
Yifan Yang,
No information about this author
Li-Wei Ou-Yang,
No information about this author
Chang Cao
No information about this author
et al.
BMC Oral Health,
Journal Year:
2025,
Volume and Issue:
25(1)
Published: April 9, 2025
This
study
aims
to
evaluate
the
efficacy
of
combining
coronally
advanced
flap
(CAF)
technique
with
concentrated
growth
factor
(CGF)
in
treatment
gingival
recession
(GR),
and
compare
this
approach
other
alternative
treatments.
systematic
review
meta-analysis
included
randomized
controlled
trials
(RCTs)
comparing
CAF
combined
CGF
treatments
for
root
coverage
procedures.
Included
studies
evaluated
systemically
healthy
adults
(>
18
years)
Miller
Class
I/II
or
Cairo
RT1
recessions.
Primary
outcomes
were
complete
(CRC)
mean
(MRC);
secondary
changes
keratinized
tissue
width
(KTW),
thickness
(GT),
clinical
attachment
level
(CAL),
(RW),
depth
(RD),
probing
(PD).
A
comprehensive
search
was
conducted
across
multiple
databases,
including
PubMed,
Scopus,
Cochrane
Library,
Web
Science,
Embase,
up
November
9,
2024.
The
protocol
prospectively
registered
PROSPERO
(CRD42024556815).
Statistical
analyses
performed
using
Review
Manager
5.4.1.
Eight
meta-analysis.
Compared
alone,
combination
significantly
improved
CRC
(OR
=
1.79,
P
0.04),
MRC
(MD
10.38%,
KTW
0.40
mm,
0.02),
GT
0.26
<
0.00001),
CAL
0.36
0.03).
connective
graft
(CTG)
showed
superior
compared
+
0.25,
0.009).
However,
no
significant
differences
found
between
CTG
MRC,
CAL,
KTW,
RD,
RW,
PD.
Additionally,
observed
when
PRF
all
parameters
(all
>
0.05).
findings
indicate
that
CAF/CGF
improves
treating
GR
may
be
a
viable
is
not
applicable.
Further
are
needed
validate
GR.
In
cases
where
applicable,
serve
as
class
I
II
Language: Английский
Imaging Characteristics of CBCT as the Gold Standard for Diagnosis and Follow-up of MRONJs
Current Oral Health Reports,
Journal Year:
2025,
Volume and Issue:
12(1)
Published: April 11, 2025
Language: Английский
Does platelet‐rich fibrin enhance the outcomes of peri-implant soft tissues? A systematic review
BMC Oral Health,
Journal Year:
2025,
Volume and Issue:
25(1)
Published: April 22, 2025
Language: Английский
In vitro comparison of the effects of titanium-prepared platelet-rich fibrin and leukocyte platelet-rich fibrin on osteoblast behavior and their gen expression
Melike Baygın,
No information about this author
Aris Çakiris,
No information about this author
Ayşegül Yabacı
No information about this author
et al.
BMC Oral Health,
Journal Year:
2024,
Volume and Issue:
24(1)
Published: Dec. 26, 2024
To
compare
the
effects
of
titanium-prepared
platelet-rich
fibrin
(T-PRF)
and
leukocyte
(L-PRF)
on
osteoblasts.
Venous
blood
samples
were
collected
from
ten
volunteer
patients
to
obtain
T-PRF
L-PRF.
The
group
was
labelled
as
Group
T,
L-PRF
L,
control
group,
which
includes
only
osteoblasts,
K.
PRF
added
cultured
osteoblast
cells
cell
proliferation
assessed
using
an
MTT
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium
bromide)
assay.
effect
different
groups
observed
for
72
h
results
analysed
statistically.
Additionally,
real-time
polymerase
chain
reaction
(RT-PCR)
conducted
evaluate
gene
expression
levels
COL1A1,
ALP,
OCN,
RUNX2
within
48
h.
We
found
that
at
24
significantly
lower
than
those
(p
=
0.036
p
<
0.001,
respectively).
showed
increase
followed
by
a
decrease
seen
both
24–48
48–72-hour
intervals.
changes
in
COLA1,
genes
did
not
differ
among
>
0.05).
In
this
study,
we
investigated
over
72-hour
period.
Both
improved
proliferation,
however
consistent
up
h,
contrast
group.
No
differences
found.
However,
osteoblastic
marker
can
be
expressed
longer
time
periods.
Therefore,
long-term
studies
are
needed.
Language: Английский
Evaluating the effectiveness of advanced platelet-rich fibrin, photobiomodulation, pentoxifylline, and Alveogyl in the treatment of alveolar osteitis: a randomized controlled clinical trial
BMC Oral Health,
Journal Year:
2024,
Volume and Issue:
24(1)
Published: Dec. 26, 2024
Alveolar
osteitis
is
a
type
of
small-scale
osteomyelitis
the
alveolar
bone
that
occurs
after
tooth
extraction,
etiology
which
remains
unknown,
and
alternative
methods
are
being
investigated
for
its
treatment.
The
aim
this
study
was
to
compare
effectiveness
advanced
platelet-rich
fibrin
(A-PRF),
photobiomodulation
(PBM),
Alveogyl
(butamben,
idoform,
eugenol),
have
shown
success
in
treatment
osteitis,
with
pentoxifylline
(PTX)
determine
whether
PTX
could
be
an
osteitis.
This
included
80
healthy
volunteers
diagnosed
extraction
sockets
their
mandibular
first,
second,
third
molars.
patients
were
divided
into
four
groups,
20
each
group:
A-PRF,
PBM,
PTX,
Alveogyl.
After
physiological
saline
irrigation,
treated
according
respective
group.
followed
up
on
2nd,
4th,
7th,
14th
days.
Primary
outcomes
pain
assessment
evaluation
soft
tissue
healing.
Pain
assessed
via
visual
analog
scale
(VAS),
healing
evaluated
Landry
Healing
Index
(LHI),
granulation
measured.
Age
sex
used
as
variables.
data
analyzed
ANOVA
post
hoc
tests
groups.
There
no
statistically
significant
difference
mean
VAS
score
between
groups
(p
>
0.05).
However,
degree
reduction
increased
following
order:
In
LHI
data,
there
scores
favored
preoperatively
PBM
at
2nd
week
<
Statistically
differences
observed
measurements
preoperative
day,
well
Days
4
7,
favor
Day
7
greatest
increase
A-PRF
group,
whereas
change
did
not
produce
healing,
although
periods
when
it
showed
results
similar
those
PBM.
score,
terms
age
within
time
followed.
findings
indicate
has
efficacy
wound
analgesic
properties
used,
does
offer
advantages.
Compared
other
methods,
provided
better
particularly
regarding
retrospectively
registered
clinical
trial
registry
number
TCTR20231014003
14.10.2023.
Language: Английский